CN105296580A - Fermentation medium of recombinant human epidermal growth factor - Google Patents
Fermentation medium of recombinant human epidermal growth factor Download PDFInfo
- Publication number
- CN105296580A CN105296580A CN201510843380.XA CN201510843380A CN105296580A CN 105296580 A CN105296580 A CN 105296580A CN 201510843380 A CN201510843380 A CN 201510843380A CN 105296580 A CN105296580 A CN 105296580A
- Authority
- CN
- China
- Prior art keywords
- obtains
- distiller
- growth factor
- steam
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a fermentation medium of a recombinant human epidermal growth factor. The medium is prepared from the following components by weight percent: 5.0-7.0% of glycerin, 3.0-3.5% of yeast nitrogen base (YNB), 1.8-2.2% of trace metal ion, 0.5-1.0% of biotin, 0.5-1.0% of an accelerant and the balance of water, wherein the trace metal ion is one of ferric trichloride, calcium chloride, sodium molybdate, zinc chloride, copper sulfate, boric acid and aluminum sulfate; the pH is adjusted to be 5.5-6.5 through a phosphate buffer solution. According to the invention, the used plant raw material components are subjected to steam explosion, distillation, and treatment by a high shear homogenizer so as to obtain a nano-emulsion plant oil component which has good compatibility with other components in the medium; the plant raw material components are added into the medium to be used as the accelerant, so that compared with the prior art, the fermentation medium disclosed by the invention has the advantage that the yield of fermentation broth is increased by 20-25%.
Description
Technical field
The present invention relates to biological technical field, particularly relate to recombinant human epidermal growth factor fermentation substratum.
Background technology
Urogastron is a kind of growth regulator found from mouse submandibular gland in the sixties in last century by people such as Cohen, is made up of 53 amino acid, and research confirms that it has the effect stimulated cellular proliferation widely.1975, the people such as Starkey, Cohen were extracted human epidermal growth factor (humanEpidermalGrowthFactor, hEGF) from people's urine, have highly consistent structure, and have consistent biologic activity with M-EGF.Urogastron is extensively present in the various tissue of human body, various kinds of cell can be stimulated to breed, mainly the propagation of epithelial cell and endotheliocyte, and this is by working in conjunction with the EGF-R ELISA (EGFR) on cytolemma.EGF is partly combined outward by the film with cell receptor, activates its tyrosine kinase activity, inducible protein phosphorylation, starts DNA synthesis, activator RNA, protein synthesis, promotes hyperplasia, divides a word with a hyphen at the end of a line.
Urogastron is extensively present in various tissue in human body, and content is atomic, has vital role for the normal physiological function maintaining the various histoorgan of human body (as angle conjunctiva, skin, various mucous membrane, body of gland etc.).With advancing age, body entocuticle growth factor levels declines gradually, show as aging and the degeneration of related tissue's organ, the particularly aging of epithelium, therefore, in time to human body supplementary table skin growth factor, can safeguard human normal function and delay senility, this is the application foundation of Urogastron in beauty and health care industry.In addition, when the impaired grade of human body, endogenous epidermal growth factor can not meet a large amount of needs of tissue repair, in time to damaged part supplementary table skin growth factor, the reparation of impaired when injected organism tissue can be promoted, apply widely clinically, as the corneal epithelial defect reparation caused for a variety of causes such as wound, inflammation, operation, chemical burn and xerophthalmia, the reparation of the various skins such as burn, wound, surgical operation, inflammation, ulcer and Mucosa Defect.
At present, to Urogastron and the existing research of recombinant human epidermal growth factor, such as Chinese patent 97115284.5, disclose epdermal growth favtur (hEGF) engineering bacteria and use the method for this bacterium preparation table skin growth factor, researchist can obtain recombinant human epidermal growth factor (or being called recombinant human epidermal growth factor stoste) by Urogastron.Science and technology in continuous progress, for the research of Urogastron and recombinant human epidermal growth factor also in the middle of constantly carrying out.
Summary of the invention
The object of this invention is to provide recombinant human epidermal growth factor fermentation substratum, this substratum is made up of following part by weight composition:
Described trace metal ion is the one in iron trichloride, calcium chloride, Sodium orthomolybdate, zinc chloride, copper sulfate, boric acid, Tai-Ace S 150;
PH is adjusted to be 5.5-6.5 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, burstpressures 3.0-3.5Mpa, and the dwell time maintains 150-200s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 30-40m/s, time 3-5min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
Preferred further, this substratum is made up of following part by weight composition:
Described trace metal ion is the one in iron trichloride, calcium chloride, Sodium orthomolybdate, zinc chloride, copper sulfate, boric acid, Tai-Ace S 150;
PH is adjusted to be 6.0 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, burstpressures 3.0-3.5Mpa, and the dwell time maintains 150-200s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 30-40m/s, time 3-5min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
Water of the present invention meets pharmaceutical industry standard.
Substratum of the present invention is conventionally prepared.
The usage quantity of Japanese Honeysuckle of the present invention, the volume after preferably pulverizing is equivalent to the 1/4-1/3 of steam explosion tank volume.
Compared with prior art, tool of the present invention has the following advantages:
1, the plant material composition that the present invention uses have passed through steam explosion, distillation, high-shear homogenizing machine process, obtains the plant oil components of nanometer emulsus, and in substratum, the consistency of other formulas is good.
2, the present invention is by adding plant material composition in the medium as promotor, and compared to the prior art, expressing output can improve 20-25%.
Embodiment
With embodiment, the invention will be further described below, but the present invention is not limited to these embodiments.
Embodiment 1:
Recombinant human epidermal growth factor fermentation substratum, this substratum is made up of following part by weight composition:
Described trace metal ion is iron trichloride;
PH is adjusted to be 5.5 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, and volume is equivalent to 1/3 of steam explosion tank volume, burstpressures 3.5Mpa, and the dwell time maintains 150s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 40m/s, time 3min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
Embodiment 2:
Recombinant human epidermal growth factor fermentation substratum, this substratum is made up of following part by weight composition:
Described trace metal ion is calcium chloride;
PH is adjusted to be 6.5 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, and volume is equivalent to 1/4 of steam explosion tank volume, burstpressures 3.0Mpa, and the dwell time maintains 200s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 30m/s, time 5min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
Embodiment 3:
Recombinant human epidermal growth factor fermentation substratum, this substratum is made up of following part by weight composition:
Described trace metal ion is in Sodium orthomolybdate, zinc chloride, copper sulfate, boric acid, Tai-Ace S 150;
PH is adjusted to be 6.0 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, and volume is equivalent to 1/3 of steam explosion tank volume, burstpressures 3.0Mpa, and the dwell time maintains 180s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 35m/s, time 4min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
Claims (3)
1. recombinant human epidermal growth factor fermentation substratum, is characterized in that, this substratum is made up of following part by weight composition:
Described trace metal ion is the one in iron trichloride, calcium chloride, Sodium orthomolybdate, zinc chloride, copper sulfate, boric acid, Tai-Ace S 150;
PH is adjusted to be 5.5-6.5 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, burstpressures 3.0-3.5Mpa, and the dwell time maintains 150-200s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 30-40m/s, time 3-5min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
2. recombinant human epidermal growth factor fermentation substratum according to claim 1, is characterized in that, this substratum is made up of following part by weight composition:
Described trace metal ion is the one in iron trichloride, calcium chloride, Sodium orthomolybdate, zinc chloride, copper sulfate, boric acid, Tai-Ace S 150;
PH is adjusted to be 6.0 with phosphate buffered saline buffer;
Described promotor adopts following methods preparation:
1) Feedstock treating: Japanese Honeysuckle is clean, drying, pulverizing;
2) Steam explosion treatment: by step 1) material that obtains puts into steam explosion tank, burstpressures 3.0-3.5Mpa, and the dwell time maintains 150-200s;
3) distillation process: by step 2) material that obtains puts into distiller, bottom distiller, heating flame or pass into steam, when hot steam is filled in distiller, water vapour, by prolong, is introduced in condenser, again by water-and-oil separator, collect essential oil;
4) high-shear homogenizing machine process: by step 3) essential oil that obtains is by high-shear homogenizing machine process, and linear velocity 30-40m/s, time 3-5min, makes nano-emulsion, and obtains with filtering with microporous membrane is degerming.
3. recombinant human epidermal growth factor fermentation substratum according to claim 1 and 2, it is characterized in that: the usage quantity of described Japanese Honeysuckle, the volume after pulverizing is equivalent to the 1/4-1/3 of steam explosion tank volume.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510843380.XA CN105296580A (en) | 2015-11-26 | 2015-11-26 | Fermentation medium of recombinant human epidermal growth factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510843380.XA CN105296580A (en) | 2015-11-26 | 2015-11-26 | Fermentation medium of recombinant human epidermal growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105296580A true CN105296580A (en) | 2016-02-03 |
Family
ID=55194402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510843380.XA Pending CN105296580A (en) | 2015-11-26 | 2015-11-26 | Fermentation medium of recombinant human epidermal growth factor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105296580A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107522242A (en) * | 2017-10-13 | 2017-12-29 | 桂林融通科技有限公司 | A kind of additive for reducing heavy metal seawater and being damaged to big oyster active oxygen radical |
| CN107628652A (en) * | 2017-10-13 | 2018-01-26 | 桂林融通科技有限公司 | A kind of additive for reducing heavy metal seawater and being influenceed on big oyster lysozyme activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210145A (en) * | 1997-08-29 | 1999-03-10 | 中国医学科学院基础医学研究所 | Engineering bacteria for epidermal growth factor and preparation of epidermal growth factor by using this bacteria |
| CN101492675A (en) * | 2008-01-21 | 2009-07-29 | 吉林圣元科技有限责任公司 | Method for producing recombinant human epidermal growth factor acceptor 2 cytoplasmic region with methylotrophy yeast |
-
2015
- 2015-11-26 CN CN201510843380.XA patent/CN105296580A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210145A (en) * | 1997-08-29 | 1999-03-10 | 中国医学科学院基础医学研究所 | Engineering bacteria for epidermal growth factor and preparation of epidermal growth factor by using this bacteria |
| CN101492675A (en) * | 2008-01-21 | 2009-07-29 | 吉林圣元科技有限责任公司 | Method for producing recombinant human epidermal growth factor acceptor 2 cytoplasmic region with methylotrophy yeast |
Non-Patent Citations (8)
| Title |
|---|
| JOAN LIN CEREGHINO等: "Heterologous protein expression in the methylotrophic yeast Pichia pastoris", 《FEMS MICROBIOLOGY REVIEWS》 * |
| 崔建云主编: "《食品加工机械与设备》", 30 June 2008 * |
| 廖小金等: "重组人表皮生长因子在毕赤酵母中的表达纯化及鉴定", 《厦门大学学报(自然科学版)》 * |
| 王郅媛等: "抗衰老研究新模型—酵母细胞活性氧代谢研究进展", 《食品科学》 * |
| 肖安风等: "毕赤酵母发酵过程胞内活性氧的定量分析", 《泉州师范学院学报(自然科学)》 * |
| 肖安风等: "流式细胞术检测毕赤酵母发酵过程中胞内活性氧水平", 《生物工程学报》 * |
| 陈建烟等: "植物精油生物活性作用机理研究进展", 《天然产物研究与开发》 * |
| 黄秉仁等: "甲基营养型酵母系统表达的重组人表皮生长因子的纯化及其性质", 《中国医学科学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107522242A (en) * | 2017-10-13 | 2017-12-29 | 桂林融通科技有限公司 | A kind of additive for reducing heavy metal seawater and being damaged to big oyster active oxygen radical |
| CN107628652A (en) * | 2017-10-13 | 2018-01-26 | 桂林融通科技有限公司 | A kind of additive for reducing heavy metal seawater and being influenceed on big oyster lysozyme activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105238832A (en) | Culture medium for recombined human epidermal growth factor fermentation | |
| CN105296572A (en) | Medium used for fermenting recombinant human epidermal growth factor | |
| CN103520082B (en) | Anti-aging composition containing epidermal growth factor and preparation method thereof | |
| CN103393585B (en) | Fibroblast liquid for beauty treatment and preparation method thereof | |
| CN105708724A (en) | Cosmetic composition for repairing skin | |
| CN105296580A (en) | Fermentation medium of recombinant human epidermal growth factor | |
| CN105296573A (en) | Culture medium for fermentation for recombinant human epidermal growth factor | |
| CN116535520A (en) | Extracellular matrix protein fusion protein and preparation method and application thereof | |
| CN105296576A (en) | Fermentation method of recombinant human epidermal growth factor | |
| CN107320419A (en) | A kind of gentle reparation urea frost | |
| CN106109391A (en) | A kind of potent moisture retention water and preparation method thereof | |
| JP2005330285A (en) | Skin moisturizing cosmetic composition | |
| WO2016090892A1 (en) | Water-soluble gel for treating diabetic foot | |
| CN105296577A (en) | Culture medium for recombinant human epidermal growth factor fermentation | |
| TW201701868A (en) | Personal cleansing and preparation method | |
| CN107029115A (en) | A kind of natural hair-loss preventing and hair-restoring stem of noble dendrobium caul-fat | |
| CN105331660A (en) | Preparation method of recombinant human epidermal growth factor stock solution | |
| JP2014159389A (en) | Filaggrin production promoter and external preparation for skin | |
| CN105296578A (en) | Fermentation process of recombinant human epidermal growth factor | |
| CN105296581A (en) | Fermentation technology for recombinant human epidermal growth factor | |
| CN105296575A (en) | Fermentation method for recombinant human epidermal growth factor | |
| CN105255976A (en) | Manufacturing process of recombined human epidermal growth factors | |
| CN105456146A (en) | High-strength anti-ultraviolet-ray silk fibroin sunscreen cream | |
| CN105296579A (en) | RhEGF (recombinant human Epidermal Growth Factor) liquid concentrate preparation technology | |
| CN105274173A (en) | Recombinant human epidermal growth factor (hEGF) original liquor production process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |